Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK and PD of GS-248 in Healthy Subjects
NCT04036227Phase 1Completed
- Sponsor
- Gesynta Pharma
- Start
- Jul 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vipoglanstat in systemic sclerosis (SSc) (4 arms), sponsored by Gesynta Pharma. Primary endpoints: Number of Treatment Related Adverse Events at 20 days, Clinically Significant Changes in ECG at 20 days and 3 more. Started Jul 2019; status: completed.
02
Drugs
vipoglanstat
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT04036227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04036227.